RxNews Recap for Thursday 11-05-09 Print E-mail
By Mary Davila   
Thursday, 05 November 2009 18:47
Below is a list of the companies that made news in the healthcare sector on Thursday, November 05, 2009.


Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

CVS Caremark (NYSE:CVS) announced the appointment of David M. Denton to the new role of Executive Vice President and Chief Financial Officer, effective January 1, 2010. Denton will succeed David Rickard who announced in February of this year his intention to retire as CFO.

NovaDel Pharma Inc. (NYSE:NVD), announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaMist™ Oral Spray spray technology.

NexMed, Inc. (Nasdaq:NEXM), a developer of innovative topical products based on the NexACT® technology, announced management will hold a conference call to discuss 2009 third quarter financial results and ongoing corporate activities, on Tuesday, November 10, 2009 at 10:00 a.m. EST.

IMS Health (NYSE:RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, announced it has entered into a definitive agreement to be acquired by investment funds managed by TPG Capital (“TPG”) and the CPP Investment Board (“CPPIB”) in a transaction with a total value of $5.2 billion, including the assumption of debt.

StemCells, Inc. (NASDAQ:STEM) reported financial results for the third quarter ended September 30, 2009.

EpiCept Corporation (Nasdaq:EPCT) announced it will host a conference call to discuss third quarter 2009 operating and financial results on Tuesday, November 10, 2009 at 9:00 a.m. EST. The call will follow the release of these financial results earlier in the day at 12:01 a.m. EST.

BMP Sunstone Corporation (Nasdaq:BJGP) announced the Company plans to release third quarter 2009 financial results on Monday, November 9, 2009, after the market closes.

Transgenomic, Inc. (OTC:TBIO) announces the following Webcast:  What: Transgenomic, Inc. Third Quarter 2009 Earnings Release Conference Call When: Thursday, November 5, 2009 @ 5:00 p.m. Eastern.

Unilife Medical SolutionsLimited (OTC:UNIFF) wishes to advise shareholders of the release of a Finance News Network interview conducted recently with Unilife CEO Alan Shortall.

Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) announced its financial results for the third quarter ended September 30, 2009.

VIVUS, Inc. (Nasdaq:VVUS) announced Leland Wilson, chief executive officer, will present an overview of the company at Merriman Corhan Ford's 6th Annual Investor Summit.

MAP Pharmaceuticals, Inc. (Nasdaq:MAPP) announced financial results for the third quarter ended September 30, 2009.

Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced Anthony S. Marucci, President and Chief Executive Officer of Celldex Therapeutics, Inc., will present at Merriman Curhan Ford’s 6th Annual Investor Summit at the Sofitel Hotel, New York City on Tuesday, November 10, 2009 at 2:40 pm, EST.

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at Credit Suisse’s 2009 Healthcare Conference in Phoenix, Arizona at 8:00 a.m., local time (10:00 a.m. ET) on Thursday, November 12, 2009.

Levi & Korsinsky is investigating the Board of Directors of IMS Health Inc. (NYSE:RX) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to private equity firm TPG and the CPP Investment Board of Toronto ("CPP").

OncoVista Innovative Therapies, Inc. (OTC:OVIT) reported strong growth in revenue, in the second quarter of 2009.

CVS Caremark Corporation (NYSE:CVS) announced its Board of Directors has approved a new share repurchase program for up to $2.0 billion of its outstanding common stock.

Emergent BioSolutions Inc. (NYSE:EBS) announced its financial results for the third quarter and nine months ended September 30, 2009.

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, announced financial results for the quarter ended September 30, 2009.

Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, reported its financial results for the third quarter ended September 30, 2009.

Life Sciences Research, Inc. (NYSE:LSR) announced financial results for the three and nine months ended September 30, 2009.

Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, announced financial results for the third quarter ended September 30, 2009.

S3 Investment Company, Inc. (OTC:SIVC) issued comment from Chairman and CEO Jim Bickel regarding the recent progress of its wholly owned subsidiary businesses, Redwood Capital and Redwood Medical, both of which operate in the China market.

Bristol-Myers Squibb Company (NYSE:BMY) announced the U.S. Food and Drug Administration (FDA) has approved a labeling update for REYATAZ® to include long-term data from the CASTLE Study.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter